Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Structural modifications of bryostatin 2.

G R Pettit1, D Sengupta, P M Blumberg

  • 1Cancer Research Institute, Arizona State University, Tempe 85287-1604.

Anti-Cancer Drug Design
|April 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Evidence for the Collective Nature of Radial Flow in Pb+Pb Collisions with the ATLAS Detector.

Physical review letters·2026
Same author

Enriching African genome representation through the AGenDA project.

Nature·2026
Same author

Evidence for the Dimuon Decay of the Higgs Boson in pp Collisions with the ATLAS Detector.

Physical review letters·2025
Same author

Correlates of HIV-1 control after combination immunotherapy.

Nature·2025
Same author

Evidence for Longitudinally Polarized W Bosons in the Electroweak Production of Same-Sign W Boson Pairs in Association with Two Jets in pp Collisions at sqrt[s]=13  TeV with the ATLAS Detector.

Physical review letters·2025
Same author

Observation of tt[over ¯] Production in Pb+Pb Collisions at sqrt[s_{NN}]=5.02  TeV with the ATLAS Detector.

Physical review letters·2025
Same journal

Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA).

Anti-cancer drug design·2002
Same journal

Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.

Anti-cancer drug design·2002
Same journal

The inhibition of protein phosphatases 1 and 2A: a new target for rational anti-cancer drug design?

Anti-cancer drug design·2002
Same journal

Photokilling of cultured tumour cells by the porphyrin derivative CF3.

Anti-cancer drug design·2002
Same journal

Cyclohexylamino-demethoxy-hypocrellin B and photodynamic therapy decreases human cancer in vitro.

Anti-cancer drug design·2002
Same journal

Synthesis and anticancer activity of nordihydroguaiaretic acid (NDGA) and analogues.

Anti-cancer drug design·2002
See all related articles

Investigating bryostatin 2 structure-activity relationships, researchers found that reducing its side-chain diene system and further hydrogenation to octahydrobryostatin 2c progressively decreased P388 cell line inhibition. Esterification at C-7 also impacted activity.

Area of Science:

  • Marine natural products chemistry
  • Medicinal chemistry
  • Cancer biology

Background:

  • Bryostatins are a class of marine natural products with potent biological activities.
  • Bryostatin 2 is a key analog investigated for its anti-cancer potential.
  • Structure-activity relationship (SAR) studies are crucial for optimizing drug candidates.

Purpose of the Study:

  • To elucidate the SAR of bryostatin 2 by synthesizing and evaluating various derivatives.
  • To assess the impact of structural modifications on P388 lymphocytic leukemia cell line inhibition.
  • To determine the effect of these modifications on protein kinase C binding.

Main Methods:

  • Stepwise catalytic hydrogenation of bryostatin 2 to generate saturated ester 2a, hexahydro derivative 2b, and octahydrobryostatin 2c.

Related Experiment Videos

  • Evaluation of P388 cell line inhibition using ED50 values for each derivative.
  • Structural modifications including esterification at the C-7 position.
  • Assessment of protein kinase C binding for all synthesized derivatives.

    • Main Results:

    • Reduction of the side-chain diene system in 2a showed minimal impact on P388 cell line inhibition.
    • Further hydrogenation to hexahydro (2b) and octahydro (2c) derivatives progressively reduced P388 cell line activity.
    • Esterification at the C-7 position significantly altered the P388 lymphocytic leukemia cell line response.
    • All derivatives were evaluated for their binding affinity to protein kinase C.

    Conclusions:

    • The saturation of the side-chain diene system and further hydrogenation of bryostatin 2 lead to a decrease in anti-leukemic activity.
    • The C-7 position is critical for the activity of bryostatin 2 against P388 lymphocytic leukemia.
    • These findings provide valuable insights for the design of novel bryostatin analogs with improved therapeutic potential.